We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Chinese drugmaker Clover Biopharmaceuticals has dosed the first participants in a phase 1 trial of its COVID-19 vaccine candidate, an Australian study that’s also evaluating two adjuvants contributed by its research partners. Read More
The UK government’s decision to ban the export of dexamethasone, the inexpensive anti-inflammatory drug that’s shown promise as a COVID-19 treatment, is getting pushback from within the country. Read More
Amarin has settled with Canada-based generic drugmaker Apotex to avoid patent litigation relating to its planned generic of Amarin’s cardiovascular drug Vascepa (icosapent ethyl). Read More
The UK has authorized the use of the corticosteroid dexamethasone to reduce the risk of death in COVID-19 patients requiring ventilation or oxygen. Read More
A majority of European clinical trials of COVID-19 drugs are being run by universities and companies who either lack experience or have a poor track record in uploading their results to the EU’s trial database, which could lead to wasted research, according to a new report. Read More
A small study of early COVID-19 patients in Italy showed Roche’s Actemra (tocilizumab) provided no benefit, the Italian Medicines Agency (AIFA) said. Read More
The FDA has been forced to streamline its guidance development process during the COVID-19 pandemic, and the change is likely to shape its approach beyond the pandemic, says Center for Biologics Evaluation and Research (CBER) Director Peter Marks. Read More